Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus SER A GEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus SER A GEN.
ALDORIL 15 vs SER-A-GEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
500 mg orally once daily.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination